Format

Send to:

Choose Destination
See comment in PubMed Commons below
Proteome Sci. 2014 Jul 12;12:40. doi: 10.1186/1477-5956-12-40. eCollection 2014.

Automated quantitative multiplex immunofluorescence in situ imaging identifies phospho-S6 and phospho-PRAS40 as predictive protein biomarkers for prostate cancer lethality.

Author information

  • 1Metamark Genetics Inc, Cambridge, MA, USA.
  • 2Metamark Genetics Inc, Cambridge, MA, USA ; Current address: Atreca, San Carlos, CA, USA.
  • 3Metamark Genetics Inc, Cambridge, MA, USA ; Current address: Moderna, Cambridge, MA, USA.
  • 4Department of Pathology, Yale University Medical School, New Haven, CT, USA.
  • 5Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON, Canada.
  • 6Metamark Genetics Inc, Cambridge, MA, USA ; Current address: XTuit Pharmaceuticals, Inc, Cambridge, MA, USA.

Abstract

BACKGROUND:

We have witnessed significant progress in gene-based approaches to cancer prognostication, promising early intervention for high-risk patients and avoidance of overtreatment for low-risk patients. However, there has been less advancement in protein-based approaches, even though perturbed protein levels and post-translational modifications are more directly linked with phenotype. Most current, gene expression-based platforms require tissue lysis resulting in loss of structural and molecular information, and hence are blind to tumor heterogeneity and morphological features.

RESULTS:

Here we report an automated, integrated multiplex immunofluorescence in situ imaging approach that quantitatively measures protein biomarker levels and activity states in defined intact tissue regions where the biomarkers of interest exert their phenotype. Using this approach, we confirm that four previously reported prognostic markers, PTEN, SMAD4, CCND1 and SPP1, can predict lethal outcome of human prostate cancer. Furthermore, we show that two PI3K pathway-regulated protein activities, pS6 (RPS6-phosphoserines 235/236) and pPRAS40 (AKT1S1-phosphothreonine 246), correlate with prostate cancer lethal outcome as well (individual marker hazard ratios of 2.04 and 2.03, respectively). Finally, we incorporate these 2 markers into a novel 5-marker protein signature, SMAD4, CCND1, SPP1, pS6, and pPRAS40, which is highly predictive for prostate cancer-specific death. The ability to substitute PTEN with phospho-markers demonstrates the potential of quantitative protein activity state measurements on intact tissue.

CONCLUSIONS:

In summary, our approach can reproducibly and simultaneously quantify and assess multiple protein levels and functional activities on intact tissue specimens. We believe it is broadly applicable to not only cancer but other diseases, and propose that it should be well suited for prognostication at early stages of pathogenesis where key signaling protein levels and activities are perturbed.

KEYWORDS:

Biomarkers; Object recognition; Prostate cancer; Protein activity states; Quantitative multiplex immunofluorescence

PMID:
25075204
[PubMed]
PMCID:
PMC4114438
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for BioMed Central Icon for PubMed Central
    Loading ...
    Write to the Help Desk